Targeted Therapeutics
For people who suffer from gastrointestinal diseases, delivering therapeutics directly to the site of disease could enable safer and more effective drug therapies.
Encapsulating Innovation
Our mission is to reimagine therapeutics and their delivery.
We’re innovating smart capsule technology to deliver the right dose to the right place, safely.
Systemic Therapeutics
Our ingestible technology is designed to enable needle-free, systemic delivery of large molecules for better management of chronic diseases.
Press Releases
Publications
Twitter Feed
;
$BIOR received notification from Nasdaq that the company complies with all applicable continued listing standards.
0001193125-23-011988 | 8-K | Biora Therapeutics, Inc.
The Investor Relations website contains information about Biora Therapeutics, Inc.'s business for stockholders, potential ...
investors.bioratherapeutics.com
$BIOR presents data from device performance study with repeat doses in both fasted and fed states at Crohn’s & Colitis Congress #IBD #colitis #UC #CCCongress23 https://investors.bioratherapeutics.com/news-releases/news-release-details/biora-therapeutics-presents-data-device-performance-study-repeat
At the Crohn's & Colitis Congress next week, we are presenting the first detailed results from a human study demonstrating device function when administered with food, potentially enabling non-fasted administration. https://investors.bioratherapeutics.com/news-releases/news-release-details/biora-therapeutics-announces-two-poster-presentations-crohns #IBD #colitis #UC #CCCongress23 $BIOR
Connect with us